NSAID-induced Gastrointestinal Injury: A Focused Update for Clinicians

Journal of Clinical Gastroenterology

Volumn 50, Issue 1, 2016, Pages 5-10

  Scheiman, James M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

GI bleeding; NSAIDS; peptic ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; IBUPROFEN; LANSOPRAZOLE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL CLEARANCE; CLINICAL TRIAL (TOPIC); COLON DISEASE; CONGESTIVE HEART FAILURE; DIGESTIVE SYSTEM INJURY; DRUG INDUCED DISEASE; ELEVATED BLOOD PRESSURE; ENTEROPATHY; HUMAN; INTESTINE INJURY; META ANALYSIS (TOPIC); PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; TREATMENT DURATION; ULCER HEALING; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT; UPPER GASTROINTESTINAL TRACT DISEASE; UPPER GASTROINTESTINAL TRACT INJURY; ANIMAL; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; DRUG EFFECTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; PATHOPHYSIOLOGY; RISK FACTOR;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; RISK FACTORS;

EID: 84952636585     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000432     Document Type: Review

References (30)

1. Scheiman JM. Balancing risks and benefits of cyclooxygenase-2 selective NSAIDs. Gastroenterol Clin N Am. 2009;38: 305-314.
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The class study: A randomized controlled trial. JAMA. 2000;284: 1247-1255.
3. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: Randomized controlled trial. Lancet. 2004;364:665-674.
4. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: Meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769-779.
5. Jones R, Rubin G, Berenbaum F, et al. Protection of the upper gastrointestinal tract in patients taking nonsteroidal antiinflammatory drugs. Am J Med. 2008;121:464-474.
6. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med. 2006;119:624-638.
7. Calonge N, Petitti DB, DeWitt TG, et al. Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150:396-404.
8. Scheiman JM. NSAIDs, gastrointestinal injury, and cytoprotection. Gastroenterol Clin North Am. 1996;25:279-298.
9. Scheiman JM, Hindley C. Strategies to optimize NSAID therapy for patients at risk for GI and CV adverse events. Clin Ther. 2010;32:667-677.
10. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15:S5. doi:10.1186/ar4177.
11. Rostom A, Dube C, Wells G, et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev. 2004;4:CD002296.
12. Chan FK, Hung LC, Suen BY, et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347:2104-2110.
13. Lai KC, Chu KM, Hui WM, et al. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications. Am J Med. 2005;118:1271-1278.
14. Lanas A, Garcá-Rodŕguez LA, Arroyo MT, et al. Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with nonsteroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants. Am J Gastroenterol. 2007; 102:507-515.
15. Ray WA, Chung CP, Stein CM, et al. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133: 790-798.
16. Chan FK, Wong VW, Suen BY, et al. Combination of a cyclooxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: A double-blind, randomised trial. Lancet. 2007;369: 621-1626.
17. Targownik LE, Metge CJ, Leung S, et al. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs. Gastroenterology. 2008;134:937-944.
18. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med. 2001;345:1809-1817.
19. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-1080.
20. Arber N, Eagle CJ, Spicak J, et al. PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355:885-895.
21. Macdonald TM,Mackenzie IS, Wei L, et al. Methodology of a large prospective, randomised, open, blinded endpoint streamlined safety study of celecoxib versus traditional non-steroidal anti-inflammatory drugs in patients with osteoarthritis or rheumatoid arthritis: Protocol of the standard care versus celecoxib outcome trial. BMJ Open. 2013;3:1. doi:pii:e002295.
22. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus Report. Aliment Pharmacol & Ther. 2002;16:167-180.
23. Fisher L, Scheiman J. Intestinal ulcerations. In: Feldman M, Friedman LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier Saunders: Philadephia, PA; 2016:2102-2111.
24. Graham DY, Opekun AR, Willingham FF, et al. Visible smallintestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55-59.
25. Higuchi K, Umegaki E, Watanabe T, et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol. 2009;44:879-888.
26. Wallace JL, Syer S, Denou E, et al. Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis. Gastroenterology. 2011;141:1314.e1-5-1322.e1-5.
27. Chan FK, Lanas A, Scheiman J, et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): A randomised trial. Lancet. 2010;376:173-179.
28. Scheiman JM, Fendrick AMF. Summing the risks of NSAID therapy. Lancet. 2007;369:1580-1581.
29. Goldstein JL, Howard KB, Walton SM, et al. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol. 2006;4:1337-1345.
30. Bhatt D, Scheiman JM, Abraham N, et al. ACCF/ACG/AHA clinical expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastro. 2008;103:2890-2907.